abstract：:After the first wave of the tsunami of immune checkpoint inhibitors, 2016 was marked by the second wave, revealed by numerous US FDA approvals, publications and abstracts in relation with these drugs in different cancers and settings. First, we reported all new indications of anti-CTLA4, anti-programmed cell death pro...

journal_title：Immunotherapy

authors： Kourie HR,Awada G,Awada A

更新日期：2017-06-01 00:00:00

abstract：:Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

journal_title：Immunotherapy

authors： Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

更新日期：2017-06-01 00:00:00

abstract：AIM:Placenta specific 1 (PLAC1) is a protein rarely expressed in normal cells, except it is important for placental development, with a possible role in the establishment of the mother-fetus interface. The gene is also highly active in a wide variety of cancers and therefore, immunization with PLAC1 peptides could poss...

journal_title：Immunotherapy

authors： Liso A,Massenzio F,Stracci F

更新日期：2017-05-01 00:00:00

abstract：:Tumor-associated macrophages (TAMs), representing most of the leukocyte population in solid tumors, demonstrate great phenotypic heterogeneity and diverse functional capabilities under the influence of the local tumor microenvironment. These anti-inflammatory and protumorigenic macrophages modulate the local microenvi...

journal_title：Immunotherapy

authors： Petty AJ,Yang Y

更新日期：2017-03-01 00:00:00

abstract：:Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including ...

journal_title：Immunotherapy

authors： Koido S,Okamoto M,Shimodaira S,Sugiyama H

更新日期：2016-11-01 00:00:00

abstract：:HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20-30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This anti-HER2Th1 respo...

journal_title：Immunotherapy

authors： De La Cruz LM,Nocera NF,Czerniecki BJ

更新日期：2016-10-01 00:00:00

abstract：AIM:A 1-year follow-up study comparing the safety and tolerability of the dosing schedules, satisfaction and effectiveness of a novel microcrystalline tyrosine-adsorbed mite (Dermatophagoides pteronyssinus)-allergoid subcutaneous immunotherapy (Acarovac Plus™) in 30 adult patients (18-65 years) with allergic rhinitis a...

journal_title：Immunotherapy

authors： Roger A,Depreux N,Jurgens Y,Serra AT,Heath MD,Garcia G,Skinner MA

更新日期：2016-10-01 00:00:00

abstract：AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

journal_title：Immunotherapy

authors： Abdel-Rahman O

更新日期：2016-09-01 00:00:00

abstract：:Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to trea...

journal_title：Immunotherapy

authors： Aya F,Fernández-Martínez A,Gaba L,Victoria I,Tosca M,Carrera C,Prat A,Arance A

更新日期：2016-06-01 00:00:00

abstract：:Meningiomas are increasingly appreciated to share similar features with other intra-axial central nervous system neoplasms as well as systemic cancers. Immune checkpoint inhibition has emerged as a promising therapy in a number of cancers, with durable responses of years in a subset of patients. Several lines of evide...

journal_title：Immunotherapy

authors： Bi WL,Wu WW,Santagata S,Reardon DA,Dunn IF

更新日期：2016-06-01 00:00:00

abstract：:Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkabl...

journal_title：Immunotherapy

authors： Janakiram M,Pareek V,Cheng H,Narasimhulu DM,Zang X

更新日期：2016-06-01 00:00:00

abstract：:Over the last two decades, anti-CD20 monoclonal antibody (mAb) therapy has improved patient outcome in B-cell malignancies, and confirmed CD20 as an important target in chronic lymphocytic leukemia (CLL). Until recently, the gold standard was based on the utilization of rituximab combined with chemotherapy (fludarabin...

journal_title：Immunotherapy

authors： Bagacean C,Zdrenghea M,Tempescul A,Cristea V,Renaudineau Y

更新日期：2016-05-01 00:00:00

abstract：:The human IgG2 monoclonal antibody tremelimumab is an immune checkpoint inhibitor that blocks cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The therapeutic response of anti-CTLA-4 monoclonal antibodies possess unique kinetics, in that antitumor responses are often observed after initial short-term disease prog...

journal_title：Immunotherapy

authors： Shimomura A,Fujiwara Y,Kondo S,Kodaira M,Iwasa S,Kitano S,Tanabe Y,Tamura K,Yamamoto N

更新日期：2016-01-01 00:00:00

abstract：:Acute pyelonephritis is an infection of the renal parenchyma and renal pelvis. When it is caused by a typical pathogen in an immunocompetent female patient with normal urinary tract, it is considered uncomplicated. In all other cases, sepsis is the most worrisome complication. In the event of sepsis, patients should b...

journal_title：Immunotherapy

authors： Tsaganos T,Giamarellos-Bourboulis EJ

更新日期：2016-01-01 00:00:00

abstract：:Although treatment options for castration-resistant prostate cancer (CRPC) have increased over the last decade, there remains a need for strategies that can provide durable disease control and long-term benefit. Recently, immunotherapy has emerged as a viable and attractive strategy for the treatment of CRPC. To date,...

journal_title：Immunotherapy

authors： Noguchi M,Koga N,Moriya F,Itoh K

更新日期：2016-01-01 00:00:00

abstract：:Food allergy is a worldwide issue, with an estimated prevalence of 2-10%. An effective treatment is not available for people affected and the only management is the avoidance of the allergen. Oral immunotherapy and sublingual immunotherapy have been tested by several authors, in particular for milk, egg and peanuts al...

journal_title：Immunotherapy

authors： Praticò AD,Leonardi S

更新日期：2015-01-01 00:00:00

abstract：:Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growt...

journal_title：Immunotherapy

authors： Pellom ST Jr,Dudimah DF,Thounaojam MC,Sayers TJ,Shanker A

更新日期：2015-01-01 00:00:00

abstract：:Sarcoidois is an inflammatory disease of unknown origin characterized by the abnormal accumulation of noncaseating granulomas at sites of disease activity in multiple organs throughout the body with a predilection for the lungs. Because the exact trigger that leads to disease activity is still under investigation, cur...

journal_title：Immunotherapy

authors： Celada LJ,Drake WP

更新日期：2015-01-01 00:00:00

abstract：AIM:It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulat...

journal_title：Immunotherapy

authors： Newton AH,Danahy DB,Chan MA,Benedict SH

更新日期：2015-01-01 00:00:00

abstract：:Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

journal_title：Immunotherapy

authors： Nicodemus CF

更新日期：2015-01-01 00:00:00

abstract：:Epstein-Barr virus (EBV) infection is associated with a range of human malignancies of lymphocytic and epithelial cell origin. In addition to viral-mediated and genetic oncogenic events that lead to the establishment of EBV-associated malignancies, defects in the immune control of EBV likely play a significant role in...

journal_title：Immunotherapy

authors： Smith C,Khanna R

更新日期：2015-01-01 00:00:00

abstract：:The poor prognosis of pancreatic cancer patients signifies a need for radically new therapeutic strategies. Tumor-targeted oncolytic viruses have emerged as attractive therapeutic candidates for cancer treatment due to their inherent ability to specifically target and lyse tumor cells as well as induce antitumor effec...

journal_title：Immunotherapy

authors： Al Yaghchi C,Zhang Z,Alusi G,Lemoine NR,Wang Y

更新日期：2015-01-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

journal_title：Immunotherapy

authors： Tzannou I,Leen AM

更新日期：2015-01-01 00:00:00

abstract：:Lactobacilli are a group of normal microbiota whose immunomodulatory effects have been known for a long time. Recently, they have gained more attention for their direct and indirect effects on cancer cells. Several cell line experiments, animal model studies as well as clinical trials have indicated their inhibitory e...

journal_title：Immunotherapy

authors： Abedin-Do A,Taherian-Esfahani Z,Ghafouri-Fard S,Ghafouri-Fard S,Motevaseli E

更新日期：2015-01-01 00:00:00

abstract：:Melanoma antigen family A, 3 (MAGE-A3) is a cancer-testis antigen whose expression has been demonstrated in a wide array of malignancies including melanoma, brain, breast, lung and ovarian cancer. In addition, its ability to elicit spontaneous humoral and cellular immune responses has been shown in cancer patients. As...

journal_title：Immunotherapy

authors： Esfandiary A,Ghafouri-Fard S

更新日期：2015-01-01 00:00:00

abstract：:Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...

journal_title：Immunotherapy

authors： Pinelli DF,Ford ML

更新日期：2015-01-01 00:00:00

abstract：:The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, includ...

journal_title：Immunotherapy

authors： Croce M,Corrias MV,Rigo V,Ferrini S

更新日期：2015-01-01 00:00:00

abstract：:Sarcoidosis is a systemic disease with an incidence of 1 to 40 per 100 000 persons per year. It predominantly affects people in the age of 20 to 40 years old. Disease course varies from mild self-limiting to chronic debilitating and life-threatening disease. Since the cause of sarcoidosis is unknown, curative therapy ...

journal_title：Immunotherapy

authors： Crommelin HA,Vorselaars AD,van Moorsel CH,Korenromp IH,Deneer VH,Grutters JC

更新日期：2014-01-01 00:00:00

abstract：:Activation of a patient's immune system offers an attractive approach to prevent and treat hepatocellular carcinoma (HCC). However, the antitumor efficacy of current HCC vaccines was weak owing to insufficient immune activation of targeting self/tumor antigens. We recently found that epitope-optimized α-fetoprotein ef...

journal_title：Immunotherapy

authors： He Y,Hong Y,Mizejewski GJ

更新日期：2014-01-01 00:00:00

abstract：:Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

journal_title：Immunotherapy

authors： Patel SP,Osada T,Lyerly HK,Morse MA

更新日期：2014-01-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic inflammatory disease in which persistent inflammation of synovial tissue results in a progressive functional decline of the joint and premature mortality. TNF inhibitors were the first biological disease-modifying antirheumatic drugs (DMARDs) used to treat RA. Since then, new bio...

journal_title：Immunotherapy

authors： García-Hernández MH,González-Amaro R,Portales-Pérez DP

更新日期：2014-01-01 00:00:00

abstract：:Hereditary angioedema (HAE) is a relatively rare autosomal dominant disorder that is typically characterized by recurrent episodes of edema in various body locations. It is most commonly caused by an inherited deficiency of functionally active C1 esterase inhibitor (C1-INH). Replacement therapy with a human plasma-der...

journal_title：Immunotherapy

authors： Bork K

更新日期：2014-01-01 00:00:00

abstract：:Cancer-testis (CT) antigens are tumor-associated antigens attracting immunologists for their possible application in the immunotherapy of cancer. Several clinical trials have assessed their therapeutic potentials in cancer patients. Breast cancers, especially triple-negative cancers are among those with significant ex...

journal_title：Immunotherapy

authors： Ghafouri-Fard S,Shamsi R,Seifi-Alan M,Javaheri M,Tabarestani S

更新日期：2014-01-01 00:00:00

abstract：AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

journal_title：Immunotherapy

authors： Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

更新日期：2014-01-01 00:00:00

abstract：:γδ T cells are capable of recognizing tumor cells and exert potent cellular cytotoxicity against a large range of tumors, including colon cancer. However, tumors utilize numerous strategies to escape recognition or killing by patrolling γδ T cells, such a downregulation of NKG2D ligands, MICA/B and ULBPs. Therefore, t...

journal_title：Immunotherapy

authors： Ramutton T,Buccheri S,Dieli F,Todaro M,Stassi G,Meraviglia S

更新日期：2014-01-01 00:00:00

abstract：:Evaluation of: Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra25 (2014). Recently, chimeric antigen receptor (CAR) T-cell immunotherapy has entered clinical trials in patients with relapsed or refr...

journal_title：Immunotherapy

authors： Patel JM,Dale GA,Vartabedian VF,Dey P,Selvaraj P

更新日期：2014-01-01 00:00:00

abstract：:Targeted immunotherapies represent a valid strategy for the treatment of metastatic castrate-resistant prostate cancer. A randomized, double-blind, Phase II clinical trial of PROSTVAC® demonstrated a statistically significant improvement in overall survival and a large, global, Phase III trial with overall survival as...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2014-01-01 00:00:00

abstract：:Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

journal_title：Immunotherapy

authors： Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

更新日期：2014-01-01 00:00:00

abstract：:Progressive multifocal leukoencephalopathy (PML) is a rare and severe complication of natalizumab therapy in patients with multiple sclerosis and it may be accompanied by immune reconstitution inflammatory syndrome (IRIS). Here, we describe a case of abnormally severe IRIS, which occurred 2 months after natalizumab-as...

journal_title：Immunotherapy

authors： Calvi A,De Riz M,Pietroboni AM,Ghezzi L,Maltese V,Arighi A,Fumagalli GG,Jacini F,Donelli C,Comi G,Galimberti D,Scarpini E

更新日期：2014-01-01 00:00:00

abstract：AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...

journal_title：Immunotherapy

authors： Quiralte J,Justicia JL,Cardona V,Dávila I,Moreno E,Ruiz B,García MA

更新日期：2013-12-01 00:00:00